Rogers PJ, Appleton KM, Kessler D, Peters TJ, Gunnell D, Hayward RC, Heatherley SV, Christian LM, McNaughton SA, Ness AR (2007) Br J Nutr. 2008 Feb;99(2):421-31
Low dietary intakes of the n-3 long-chain PUFA (LCPUFA) EPA and DHA are thought to be associated with increased risk for a variety of adverse outcomes, including some psychiatric disorders. Evidence from observational and intervention studies for a role of n-3 LCPUFA in depression is mixed, with some support for a benefit of EPA and/or DHA in major depressive illness.
The present study was a double-blind randomised controlled trial that evaluated the effects of EPA+DHA supplementation (1.5 g/d) on mood and cognitive function in mild to moderately depressed individuals. Of 218 participants who entered the trial, 190 completed the planned 12 weeks intervention.
Compliance, confirmed by plasma fatty acid concentrations, was good, but there was no evidence of a difference between supplemented and placebo groups in the primary outcome - namely, the depression subscale of the Depression Anxiety and Stress Scales at 12 weeks. Mean depression score was 8.4 for the EPA+DHA group and 9.6 for the placebo group, with an adjusted difference of - 1.0 (95 % CI - 2.8, 0.8; P = 0.27).
Other measures of mood, mental health and cognitive function, including Beck Depression Inventory score and attentional bias toward threat words, were similarly little affected by the intervention.
In conclusion, substantially increasing EPA+DHA intake for 3 months was found not to have beneficial or harmful effects on mood in mild to moderate depression. Adding the present result to a meta-analysis of previous relevant randomised controlled trial results confirmed an overall negligible benefit of n-3 LCPUFA supplementation for depressed mood.
This randomised controlled trial set out to address an important question - namely, whether the apparent benefits of dietary supplementation with omega-3 long chain polyunsaturated fatty acids (LC-PUFA), as shown in previous controlled trials, would be evident in mild-to-moderate (i.e. sub-clinical) depression.
In previous trials, supplementation with the LC-PUFA EPA, but not DHA, has beem reported to reduce symptoms of clinical depression. Here, no significant benefits for mood were found in non-depressed individuals supplemented with a high DHA formulation. Unsurprisingly, therefore the addition of this trial to a previous meta-analysis of 11 other trials of 'omega-3' for 'mood' involving the same authors did not enhance the non-significant main effect reported there.
Dr Richardson of FAB Research was invited to provide an editorial commentary to accompany the publication of this latest trial - and the updated earlier meta-analysis - in the British Journal of Nutrition.
For the full text of this commentary, please see